2 models fit Hinge Health Inc. Class A Common Stock and they disagree: 0 of 2 land within 15% of the average.
Two or more of our models back this value.
Large discount(i)Bronze49
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionHinge Health Inc. Class A Common Stock (HNGE)
Fair value (2 models)
$163
ACCE price target
$89.00
Rating
Undervalued
Horizon
12 months
Fair value published on 20 Oct 2026, 14:06 CEST; previously $123 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 14:06 CEST.
Price used: $112 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
31.6% below
+46.1% to fair value
ACCE score
70
out of 100
Analysts
94% buy
17 covering
P/E
36.3x
forward 33.0x
1-year return
+125.1%
Dividend yield
0.00%
Hinge Health Inc. Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Hinge Health sells a digital musculoskeletal care platform, pairing wearable motion sensors and a app-based physical therapy program with clinicians who treat back, neck, and joint pain, largely sold to employers and health plans. Its moat rests on the clinical outcomes data it has accumulated and on enterprise contracts that are hard for point-solution rivals to displace once a payer builds the program into its benefits design. Revenue growth of 53% is running alongside an 84.5% gross margin and a 19.0% operating margin, a combination that suggests the model is scaling rather than buying growth. The near-term question is whether margins keep expanding as the customer base grows, since at 34.6 times trailing earnings and 33.0 times forward the stock is pricing in a good deal of that progress. At an 8.5 billion dollar market cap with no index membership yet, the name is worth a closer look at the unit economics and the retention data behind the growth rate.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Insider selling heavy
Insiders sold $93.06M of stock across the last 10 disclosed transactions and bought nothing, a one-directional signal worth weighing against the stock's valuation.
moderate
Earnings falling sharply
Earnings fell 68.4% year over year even as revenue grew 53.0%, so the profit line is not keeping pace with the top line.
moderate
Heavy short interest
Short interest stands at 10.3% of shares, meaning a meaningful bearish bet is in place against the stock.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 53.0% year over year, well above the 41.7% average annual growth over five years.
The company converted its profits into real cash, producing $171M of free cash flow over the last twelve months with a net margin of 15.2%.
Why it could disappoint
The stock trades at 34.0x forward earnings, well above the sector median of 24.2x, leaving little room for error.
Shareholders are being diluted, with the diluted share count rising 4.7% over the last fiscal year.
The valuation rests on only 2 of 3 models in the consensus, and the free cash flow yield of 2.1% is thin for a stock priced this way.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 2, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where HNGE's valuation models land
Price
$111.52
Model fair value
$163
Model range
$57.78 to $278
Fair value $163
Price $112
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores